Literature DB >> 25707333

Major drawbacks and additional benefits of agonist trigger--not ovarian hyperstimulation syndrome related.

Bruce S Shapiro1, Claus Yding Andersen2.   

Abstract

The GnRH agonist trigger alters traditional IVF paradigms when compared with hCG-only triggers. The agonist trigger induces rapid luteolysis and therefore separates the oocyte maturation aspect of LH from the luteal support previously afforded by lingering hCG. This might allow customized and more optimal luteal support. The agonist trigger option also allows continued stimulation and subsequent trigger of high responders with reasonable safety, potentially leading to retrievals of larger cohorts of mature oocytes. It may also reduce the number of retrievals needed to achieve a large family. The agonist trigger might alter other paradigms as well, such as making oocyte donation more efficient per stimulation by virtually eliminating follicular-phase cycle cancellation, coasting, and premature triggering. There are both corresponding potential benefits and drawbacks of using the agonist trigger and the shifting paradigms it allows.
Copyright © 2015 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GnRH agonist; Ovarian stimulation; human chorionic gonadotropin; in vitro fertilization

Mesh:

Substances:

Year:  2015        PMID: 25707333     DOI: 10.1016/j.fertnstert.2015.01.035

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  9 in total

Review 1.  Ovarian manipulation in ART: going beyond physiological standards to provide best clinical outcomes.

Authors:  Israel Ortega; Juan A García-Velasco; Antonio Pellicer
Journal:  J Assist Reprod Genet       Date:  2018-07-28       Impact factor: 3.412

2.  Combined GnRH-agonist and human chorionic gonadotropin trigger improves ICSI cycle outcomes in patients with history of poor fertilization.

Authors:  Rony T Elias; Nigel Pereira; Lisa Artusa; Amelia G Kelly; Monica Pasternak; Jovana P Lekovich; Gianpiero D Palermo; Zev Rosenwaks
Journal:  J Assist Reprod Genet       Date:  2017-04-13       Impact factor: 3.412

3.  A matched propensity score study of embryo morphokinetics following gonadotropin-releasing hormone agonist versus human chorionic gonadotropin trigger.

Authors:  Galia Oron; Onit Sapir; Avital Wertheimer; Yoel Shufaro; Roni Bar-Gil; Tamar Margalit; Ekaterina Shlush; Avi Ben-Haroush
Journal:  J Assist Reprod Genet       Date:  2020-09-27       Impact factor: 3.412

4.  Evaluation of dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin in improving oocyte maturity rates: A prospective randomized study.

Authors:  Nalini Mahajan; Shilpa Sharma; Puneet Rana Arora; Shalu Gupta; Kumkum Rani; Padmaja Naidu
Journal:  J Hum Reprod Sci       Date:  2016 Apr-Jun

Review 5.  GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article.

Authors:  Ashraf Alyasin; Shayesteh Mehdinejadiani; Marzieh Ghasemi
Journal:  Int J Reprod Biomed (Yazd)       Date:  2016-09

6.  Empty Follicle Syndrome Following GnRHa Trigger in PCOS Patients Undergoing IVF Cycles.

Authors:  Krishna Deepika; Davuluri Sindhuma; Bijlani Kiran; Nair Ravishankar; Praneesh Gautham; Rao Kamini
Journal:  J Reprod Infertil       Date:  2018 Jan-Mar

7.  To Compare the Effect of GnRH Agonist versus Human Chorionic Gonadotropin (HCG) Trigger on Clinical Pregnancy Rate in Intrauterine Insemination Cycle.

Authors:  Rashmi Sharma; Imlesh Meena
Journal:  J Hum Reprod Sci       Date:  2021-09-28

8.  Dual trigger improves response to ovarian stimulation and ICSI outcomes in patients with a previous r-hCG triggered ICSI cycle.

Authors:  Amanda Souza Setti; Luis Guilherme Louzada Maldonado; Daniela Paes de Almeida Ferreira Braga; Assumpto Iaconelli; Edson Borges
Journal:  JBRA Assist Reprod       Date:  2022-04-17

9.  Ectopic pregnancy risk factors for ART patients undergoing the GnRH antagonist protocol: a retrospective study.

Authors:  A Weiss; R Beck-Fruchter; J Golan; M Lavee; Y Geslevich; E Shalev
Journal:  Reprod Biol Endocrinol       Date:  2016-03-23       Impact factor: 5.211

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.